Probiotix Health (PBX.AQ) Stock Price

ProBiotix Health PLC develops probiotics to tackle cardiovascular disease and lifestyle conditions, focusing on cholesterol reduction through its LP-LDL ingredient. The company commercializes LP-LDL as an ingredient and in CholBiome products, including CholBiome, CholBiome X3, CholBiome BP, and CholBiome VH, which improve blood lipid profiles and blood pressure. ProBiotix leverages its OptiScreen and OptiBiotic platform technologies to identify metabolic pathways for potential health benefits across various diseases. The firm targets healthcare providers, supplement manufacturers, and consumers seeking natural solutions for cardiovascular health. ProBiotix Health PLC's revenue streams include selling LP-LDL as an ingredient to manufacturers and direct sales of CholBiome products under white-label and own-label arrangements. The CholBiome range serves segments such as cardiovascular health management, lifestyle disease prevention, and natural health supplements. The company's pipeline, driven by OptiScreen and OptiBiotic, supports future product development in metabolic health and disease-specific applications. The firm's business model centers on developing and commercializing probiotic solutions for cardiovascular health, with LP-LDL as the core product. CholBiome products are positioned for consumers and healthcare partners, while the OptiScreen and OptiBiotic platforms enable expansion into new therapeutic areas. ProBiotix's revenue comes from ingredient sales and branded product lines targeting health-conscious individuals and industry partners in the probiotic and supplement markets.